Adapalene Patent Expiration
Adapalene is Used for treating acne vulgaris. It was first introduced by Galderma Laboratories Lp
Adapalene Patents
Given below is the list of patents protecting Adapalene, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Differin | US7998467 | Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers | May 31, 2028 | Galderma Labs Lp |
| Differin | US8435502 | Cosmetic/dermatological compositions comprising naphtholic acid compounds and polyurethane polymers |
Sep 15, 2026
(Expired) | Galderma Labs Lp |
| Differin | US8709392 | Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers |
Sep 15, 2026
(Expired) | Galderma Labs Lp |
| Differin | US7579377 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Feb 23, 2025
(Expired) | Galderma Labs Lp |
| Differin | US7737181 | Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Aug 29, 2024
(Expired) | Galderma Labs Lp |
| Differin | US7834060 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoic acid for the treatment of dermatological disorders |
Mar 12, 2023
(Expired) | Galderma Labs Lp |
| Differin | US7838558 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Mar 12, 2023
(Expired) | Galderma Labs Lp |
| Differin | US7868044 | Method for the treatment of acne using compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid |
Mar 12, 2023
(Expired) | Galderma Labs Lp |
| Differin | US8703820 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Mar 12, 2023
(Expired) | Galderma Labs Lp |
Adapalene's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Adapalene:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Topical 5% Spironolactone Gel Versus 0.1% Adapalene Gel for Acne Vulgaris: A Randomized Split-Face Study | Assiut University | NA |
NOT YET RECRUITING
(Mar 1, 2026)
| PHASE2 |